AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01557439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Dihydrochloride 5 mg Tablets
Description: A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
Study NCT01255709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm T1: Primatene Mist HFA
Description: epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
Study NCT00931411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formulation 609580 20
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
Study NCT00931411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formulation 609580 20
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
Study NCT00931411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formulation 609209 (Lipikar Baume)
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
Study NCT00931411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formulation 609209 (Lipikar Baume)
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
Study NCT04610905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviour
Description: This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
Study NCT04610905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase physical activity
Description: This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
Study NCT01255709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm T2: Primatene Mist HFA
Description: epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
Study NCT02101125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020
Study NCT02101125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Study NCT01255709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Description: epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
Study NCT00629993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
Study NCT02635698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optifast
Description: medically-supervised weight management program
Study NCT02635698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food-Based
Description: low-energy, low-fat diet
Study NCT02287948 — intervention group
Intervention type: DEVICE
Intervention: Nintendo Wii Fit Balance Board
Description: Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials.
Study NCT00911716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00911716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00911716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT03256201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
Study NCT00911716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT03402399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Molecular analysis
Description: Blood test
Study NCT03256201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
Study NCT03256201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Exercise
Description: Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
Study NCT04255589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-495 75mg
Description: CKD-495 75mg Tab.
Study NCT02060305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab intra-articular injection
Description: Bevacizumab, 20\~40mg, intra-articular injection every 28 days for 4 times
Study NCT02378129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement Clinpro XT
Description: Clinpro XT (3M ESPE, Minnesota, USA)
Study NCT02378129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer cement Vidrion R
Description: Vidrion R (SS White, Gloucester, UK)
Study NCT01665001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment strategy: induction, consolidation, HSCT, maintenance
Description: Patients \<55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD \<0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients >55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT.
Study NCT01926405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: saliva collection
Description: collection of saliva
Study NCT00276484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
Study NCT00276484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin 40 mg by mouth, once a day for 6 weeks
Study NCT00276484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
Study NCT04184427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Power Arm
Description: Crimpable stainless steel hook placed on orthodontic base arch wire.
Study NCT04184427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior Power Arm
Description: Crimpable stainless steel hook placed on orthodontic base arch wire.
Study NCT02577991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: 10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
Study NCT02577991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
Study NCT01796600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
Study NCT03447639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation
Description: Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
Study NCT01384110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduction of glycemic index of ingested foods
Description: Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
Study NCT02017509 — intervention group
Intervention type: PROCEDURE
Intervention: Diagnostic Biopsy and Surgical Procedure
Description: A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
Study NCT02017509 — intervention group
Intervention type: PROCEDURE
Intervention: Intravoxel incoherent motion MRI (IVIM)
Description: At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
Study NCT04271111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Treatment for Interpersonal Stress
Description: Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
Study NCT04271111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Health Education Tool
Description: Intervention designed to improve physical health through exercise, eating habits, and sleep
Study NCT01384110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reduction of glycemic index of ingested foods
Description: Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
Study NCT04166201 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: double mesh hernioplasty with modified chevrel's technique
Description: hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
Study NCT02938143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Study NCT00002524 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01397175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-eluting stent
Description: Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
Study NCT02017509 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic Contrast Enhanced MRI (DCE-MRI)
Description: Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
Study NCT02017509 — intervention group
Intervention type: GENETIC
Intervention: RNA gene expression analysis
Description: RNA will be collected from biopsy and surgical tissue for gene expression analysis.
Study NCT02837705 — intervention group
Intervention type: OTHER
Intervention: blood draw
Study NCT02575014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative hyperbaric oxygen
Description: Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
Study NCT01397175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
Study NCT01397175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting stent
Description: Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
Study NCT00963339 — intervention group
Intervention type: DEVICE
Intervention: Foresee Home
Description: Home Monitoring
Study NCT03697018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia reinforced lithium silicate glass ceramic
Description: It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
Study NCT02272413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695502
Study NCT02272413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Study NCT02150668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework, Organization, and Planning Skills (HOPS) Intervention
Study NCT03697018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zirconia reinforced lithium silicate glass ceramic
Description: It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
Study NCT02167191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT
Description: 12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
Study NCT02150668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homework Support Intervention (HSI)
Study NCT03003975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI by single cryoballoon application guided by Achieve Mapping Catheter
Description: Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
Study NCT04255589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Study NCT04255589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.
Study NCT04255589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study NCT03003975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI by 2 routine cryoballoon applications
Description: Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
Study NCT03857087 — intervention group
Intervention type: DRUG
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT03857087 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Given PET/MRI
Study NCT03857087 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET/MRI
Study NCT02802280 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular risk in HCV patients
Description: Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336.
Study NCT03580031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
Study NCT03580031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 2 ml of normal saline will be injected 48 hours after first triggering dose
Study NCT02331680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Study NCT02531724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Study NCT02331680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04158518 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Toxicities reduced treatment
Description: Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor.
Study NCT04158518 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor.
Study NCT00750061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks.